Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is a clinical-stage biotechnology leader advancing targeted therapies for genetically driven neuromuscular diseases through its proprietary FORCE™ platform. This page provides investors, researchers, and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access real-time announcements including clinical trial results, research collaborations, and regulatory filings alongside analysis of pipeline advancements for conditions like myotonic dystrophy and Duchenne muscular dystrophy. Our curated news collection ensures you stay informed about therapeutic innovations leveraging Dyne's novel approach to muscle-targeted oligonucleotide delivery.
Bookmark this page for direct access to earnings reports, scientific presentations, and partnership announcements that demonstrate Dyne's commitment to addressing high unmet needs in neuromuscular care. Regularly updated to reflect the latest developments in their mission to transform treatment paradigms.
Dyne Therapeutics (Nasdaq: DYN) priced an upsized underwritten public offering of 18,980,478 common shares at $18.44 per share, expected to raise $350.0 million in gross proceeds before fees. The offering is expected to close on or about December 11, 2025, subject to customary closing conditions.
Dyne sold all shares in the offering and granted underwriters a 30-day option to purchase up to an additional 2,847,071 shares at the public offering price, less underwriting discounts and commissions.
Dyne Therapeutics (Nasdaq: DYN) announced on Dec 8, 2025 that it commenced an underwritten public offering of $300,000,000 of common stock with a 30-day option for underwriters to purchase up to an additional $45,000,000 of shares.
All shares in the proposed offering are to be sold by Dyne. The offering is subject to market and other conditions and will be made pursuant to a Form S-3 shelf registration filed on March 5, 2024. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are joint book-running managers. A preliminary prospectus supplement is expected to be filed with the SEC and final terms will appear in a final prospectus supplement.
Dyne Therapeutics (Nasdaq: DYN) announced positive topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping. The REC met its primary endpoint with muscle-content adjusted dystrophin rising to 5.46% of normal at 6 months (p<0.0001), replicating a seven-fold increase from prior MAD data.
Functional improvement was observed across six prespecified endpoints with nominal significance for TTR and 10MWR velocity, lung function (FVC%p) was preserved at 6 months, safety remained favorable across 86 participants, and Dyne plans a U.S. Accelerated Approval BLA filing in Q2 2026.
Dyne Therapeutics (Nasdaq: DYN) will announce topline results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, DYNE-251) on December 8, 2025.
The company will host an investor conference call and webcast at 8:00 a.m. ET on that day; a press release will be issued before the event. The webcast and an accompanying slide presentation will be available on Dyne’s Events & Presentations page, and a replay will be accessible for 90 days after the presentation.
Dyne Therapeutics (Nasdaq: DYN) reported Q3 2025 results and program updates. Cash, cash equivalents and marketable securities were $791.9M as of Sept 30, 2025, with an expected runway into Q3 2027. The company expects topline DELIVER REC data for z-rostudirsen (DYNE-251) in Dec 2025 to support a potential U.S. Accelerated Approval submission in Q2 2026 and a potential launch in Q1 2027 (pending Priority Review). FDA granted Breakthrough Therapy Designation to z-rostudirsen and to z-basivarsen (DYNE-101) in DM1. ACHIEVE REC enrollment for z-basivarsen (60 participants) is now expected to complete in early Q2 2026, with a potential BLA submission in early Q3 2027 and a possible U.S. launch in Q1 2028. Q3 2025 net loss was $108.0M ($0.76/share).
Dyne Therapeutics (Nasdaq: DYN) will present at multiple investor conferences in November–December 2025, featuring management fireside chats and live webcasts.
Scheduled events: Guggenheim Healthcare on Nov 10, 2025 at 10:00 a.m. ET (Boston); Stifel Healthcare on Nov 11, 2025 at 9:20 a.m. ET (New York); Jefferies Global Healthcare on Nov 17, 2025 at 3:00 p.m. GMT (10:00 a.m. ET, London); and Evercore Healthcare on Dec 2, 2025 at 9:35 a.m. ET (Coral Gables).
A live webcast will be available in the Investors & Media section at investors.dyne-tx.com, with replays accessible for 90 days.
Dyne Therapeutics (NASDAQ: DYN) announced one-year Phase 1/2 ACHIEVE data for zeleciment basivarsen (z-basivarsen, DYNE-101) in adults with myotonic dystrophy type 1 (DM1). At the selected registrational dose of 6.8 mg/kg Q8W (n=6 cohort), patients showed clinically meaningful, sustained improvements in myotonia (vHOT), multiple functional tests (10MWR, 5xSTS, 9HPT), and quantitative muscle testing across upper and lower limbs. Patient-reported MDHI improved, including six CNS-related subscales, and PGI-C/CGI-C reflected reduced overall disease burden. Safety across the 6.8 mg/kg Q8W program (n=56) showed a favorable profile with no related serious treatment-emergent adverse events. Data presented at the World Muscle Society annual congress (Oct 7–11, 2025).
Dyne Therapeutics (Nasdaq: DYN) announced on Oct 2, 2025 the appointment of Brian Posner to its Board of Directors. Posner brings 35 years of executive, investment and board leadership, including roles as president and CEO of ClearBridge Advisors (a $100 billion+ asset manager) and partner at Warburg Pincus. Dyne says the appointment comes as it transitions to a fully integrated biotech poised to commercialize its first potential product in 2027. Posner currently serves on Arch Capital Group's board and has prior board experience at Biogen and Bioverativ.
Dyne Therapeutics (Nasdaq: DYN) has received Orphan Drug designation in Japan from the Ministry of Health, Labour and Welfare for DYNE-251, its treatment for Duchenne muscular dystrophy (DMD) patients with mutations amenable to exon 51 skipping.
The ongoing DELIVER Phase 1/2 clinical trial has shown sustained functional improvement through 18 months, with significant dystrophin expression. Results from the Registrational Expansion Cohort are expected in late 2025. The Japanese designation joins existing designations in the U.S. (Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug) and Europe (Orphan Drug).
The Japanese Orphan Drug status provides benefits including development cost subsidies and potential 10-year market exclusivity upon approval, applying to diseases affecting fewer than 50,000 patients in Japan.
Dyne Therapeutics (NASDAQ: DYN), a clinical-stage company specializing in treatments for genetically driven neuromuscular diseases, has announced its participation in two major healthcare investor conferences in September 2025.
Management will present at the Cantor Global Healthcare Conference on September 5, 2025, at 9:45 a.m. ET, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 9:15 a.m. ET. Both events will take place in New York.
Investors can access live webcasts of the presentations through Dyne's website, with replays available for 90 days.
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
What is the market cap of Dyne Therapeutics (DYN)?
